Patents Assigned to BioSante Pharmaceuticals, Inc.
-
Publication number: 20130309267Abstract: Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility in methods for treating cancer.Type: ApplicationFiled: February 11, 2011Publication date: November 21, 2013Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BIOSANTE PHARMACEUTICALS, INC.Inventors: Andrew Simmons, Karin Jooss, James Allison
-
Publication number: 20130022600Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicants: Medarex, Inc., BioSante Pharmaceuticals, Inc.Inventors: Betty LI, Karin Jooss, Alan J. Korman
-
Patent number: 8287856Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.Type: GrantFiled: July 19, 2010Date of Patent: October 16, 2012Assignees: BioSante Pharmaceuticals, Inc., Medarex, Inc.Inventors: Betty Li, Karin Jooss, Alan J. Korman
-
Publication number: 20120046264Abstract: Methods for commercial production of transdermal formulations comprising a hormone compound are provided. In particular, methods for commercial scale production under an inert atmosphere of a transdermal formulation comprising a therapeutically effective amount of a hormone, preferably a testosterone compound, useful for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women are provided.Type: ApplicationFiled: August 17, 2011Publication date: February 23, 2012Applicant: BIOSANTE PHARMACEUTICALS, INC.Inventors: Stephen Simes, Linda Lieb
-
Publication number: 20120034242Abstract: The present invention in all of its associated aspects provides improved methods and compositions for treating cancer in a mammal based on the administration of the combination of a cytokine-expressing cellular vaccine and at least one additional cancer therapeutic agent or treatment to a patient with cancer, wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cellular vaccine or cancer therapeutic agent or treatment as a monotherapy.Type: ApplicationFiled: July 12, 2011Publication date: February 9, 2012Applicant: BIOSANTE PHARMACEUTICALS, INC.Inventors: Karin Jooss, Jennifer Creson, Betty Li, Rodney Prell, Sandra Aung, Marina Boris Moskalenko, Thomas Du
-
Publication number: 20120022033Abstract: Methods for decreasing the risk of cardiovascular events in postmenopausal women having a high risk for a cardiovascular event are provided. In particular, methods for decreasing the risk of cardiovascular events in postmenopausal woman at high risk for cardiovascular events by administering to the woman a therapeutically effective amount of an androgen, whereby administering the androgen decreases the risk of cardiovascular events in the woman compared to untreated postmenopausal woman at high risk for cardiovascular events are provided.Type: ApplicationFiled: July 20, 2011Publication date: January 26, 2012Applicant: BIOSANTE PHARMACEUTICALS, INC.Inventors: Stephen Simes, Michael Snabes, Joanne Zborowski
-
Publication number: 20120004204Abstract: Methods for treating female sexual dysfunction are provided. In particular, methods for treating a woman having HSDD by administering to the woman a therapeutically effective amount of an androgen, whereby the therapeutically effective amount of the androgen is administered in a manner that results in a reduction in expected number of cardiovascular events in the woman are provided.Type: ApplicationFiled: June 29, 2011Publication date: January 5, 2012Applicant: BIOSANTE PHARMACEUTICALS, INC.Inventors: Stephen Simes, Michael Snabes, Joanne Zborowski
-
Publication number: 20110159585Abstract: This invention provides compositions and methods for cryoprotection of recombinant live cancer cells. Specifically, an improved cryoprotective medium is provided which includes a hydroxyethyl starch and/or derivative thereof alone or in combination with either DMSO or glycerol.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Applicant: BIOSANTE PHARMACEUTICALS, INC.Inventors: David Frey, Andy Lin, Gautum Banik
-
Patent number: 7939271Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, immunoglobulins specific for such markers, and methods of using such markers and/or immunoglobulins to assess an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.Type: GrantFiled: March 3, 2008Date of Patent: May 10, 2011Assignee: BioSante Pharmaceuticals, Inc.Inventors: Karin Jooss, Thomas Harding, Minh Nguyen, Kathryn E. Koprivnikar
-
Patent number: 7919079Abstract: Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility in methods for treating cancer.Type: GrantFiled: March 28, 2007Date of Patent: April 5, 2011Assignees: BioSante Pharmaceuticals, Inc., The Regents of the University of CaliforniaInventors: Andrew Simmons, Karin Jooss, James Allison
-
Publication number: 20110065779Abstract: Single AAV vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single promoter. The vector constructs may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in enhanced production of biologically active immunoglobulins or fragments thereof in vitro and in vivo.Type: ApplicationFiled: March 5, 2010Publication date: March 17, 2011Applicant: BIOSANTE PHARMACEUTICALS, INC.Inventors: Jianmin Fang, Karin Jooss, Jing Jing Qian
-
Patent number: 7901902Abstract: Filamin-B peptides, compositions comprising such peptides, and methods of using such peptides to assess an immune response against such peptides are described. An immune response against the peptides correlates with an immune response, in particular a cellular immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.Type: GrantFiled: July 26, 2007Date of Patent: March 8, 2011Assignee: BioSante Pharmaceuticals, Inc.Inventors: Jooeun Bae, Karin Jooss
-
Publication number: 20110038801Abstract: Methods and compositions are provided for identifying lung cancer or a humoral immune response against lung cancer. Also disclosed are methods for determining whether a subject is responding or is likely to respond to lung cancer immunotherapy.Type: ApplicationFiled: December 19, 2008Publication date: February 17, 2011Applicant: BioSante Pharmaceuticals, Inc.Inventors: Karin Jooss, Andrew D. Simmons
-
Patent number: 7858083Abstract: Replication-competent adenoviral vectors which selectively replicate in cancer cells are provided. The replication-competent viral vectors comprise an E2F responsive promoter and/or a telomerase promoter operatively linked to an adenoviral coding region. The replication-competent adenoviral vectors effectively replicate in a variety of types of cancer cells and find broad utility in the treatment of cancer.Type: GrantFiled: December 4, 2008Date of Patent: December 28, 2010Assignee: BioSante Pharmaceuticals, Inc.Inventors: DeChao Yu, Yuanhao Li
-
Publication number: 20100285013Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.Type: ApplicationFiled: July 19, 2010Publication date: November 11, 2010Applicant: BioSante Pharmaceuticals, Inc.Inventors: Betty Li, Karin Jooss, Alan J. Korman
-
Patent number: 7714119Abstract: Single AAV vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single promoter. The vector constructs may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in enhanced production of biologically active immunoglobulins or fragments thereof in vitro and in vivo.Type: GrantFiled: July 13, 2005Date of Patent: May 11, 2010Assignee: Biosante Pharmaceuticals, Inc.Inventors: Jianmin Fang, Karin Jooss, Jing Jing Qian
-
Patent number: 7709224Abstract: Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.Type: GrantFiled: April 26, 2004Date of Patent: May 4, 2010Assignee: Biosante Pharmaceuticals, Inc.Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Jing-Jing Qian
-
Patent number: 7662623Abstract: Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.Type: GrantFiled: October 26, 2007Date of Patent: February 16, 2010Assignee: BioSante Pharmaceuticals, Inc.Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Jing-Jing Qian
-
Patent number: 7645587Abstract: The present invention provides novel, isolated, tumor-associated antigens, and methods for identifying such antigens in a biological sample, and of screening for the presence of such an antigen in a biological specimen, wherein the tumor antigen identified reacts with serum from a subject treated with a vaccine comprising a cytokine and proliferation-incompetent tumor cells which express the tumor-associated antigen. Also provided are kits for carrying out the methods of the invention.Type: GrantFiled: May 2, 2007Date of Patent: January 12, 2010Assignees: BioSante Pharmaceuticals, Inc., John Hopkins UniversityInventors: James McArthur, Ju-Fay Chang, Dale Ando, Margo Roberts, Jonathan Simons, William Nelson
-
Patent number: 7632509Abstract: Lentivector constructs for expression of recombinant proteins, polypeptides or fragments thereof and methods of making the same are described. The lentivectors typically have a self-processing cleavage sequence between a first and second protein or polypeptide coding sequence allowing for expression of a functional protein or polypeptide under operative control of a single promoter and may further include an additional proteolytic cleavage sequence which provides a means to remove the self-processing cleavage sequence from the expressed protein or polypeptide. The vector constructs find utility in methods relating to enhanced production of biologically active proteins, such as immunoglobulins or fragments thereof in vitro and in vivo.Type: GrantFiled: July 18, 2006Date of Patent: December 15, 2009Assignee: BioSante Pharmaceuticals, Inc.Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Debbie Farson, Jing Jing Qian